Small Molecules
24 August 2017
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH24 August 2017
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack23 August 2017
Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis23 August 2017
Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas22 August 2017
PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-125122 August 2017
Cardiome provides U.S. regulatory update for brinavess21 August 2017
Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder21 August 2017
New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS StudyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports